Physician profile
Sarah Smith
NPI 1194246199
$401.11
in general payments reported to CMS, 2019-2025
14 companies · $218 in 2025
The $218 reported for 2025 was more than what 77% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.67 · 2022: $34.71 · 2023: $42.27 · 2024: $78.42 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $74.87 | 2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $57.43 | 2022-2025 | Inbrija |
| Inspire Medical Systems, INC. | $40.66 | 2025 | Inspire |
| Mdd US Operations, LLC | $27.67 | 2021 | |
| Jazz Pharmaceuticals INC. | $26.70 | 2025 | |
| Lundbeck LLC | $23.79 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $22.81 | 2023 | Rexulti |
| Cranial Technologies, INC | $21.67 | 2025 | Doc Band |
| Abbvie INC. | $20.05 | 2022 | |
| Sanofi Pasteur INC. | $19.88 | 2024 | |
| Grifols USA, LLC | $19.46 | 2023 | Gamunex-C |
| Neurelis, INC. | $16.50 | 2025 | Valtoco |
| Merck Sharp & Dohme LLC | $14.93 | 2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Tanabe Pharma America, INC. | $14.69 | 2025 | Radicava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.